{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:23:27Z","timestamp":1793701407698,"version":"4.5.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"7866","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2021,7,8]]},"DOI":"10.1038\/s41586-021-03684-z","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T12:03:11Z","timestamp":1625054591000},"page":"289-294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":125,"title":["Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity"],"prefix":"10.1038","volume":"595","author":[{"given":"Agnes","family":"Mwakingwe-Omari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3078-6094","authenticated-orcid":false,"given":"Sara A.","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquelyn","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahand","family":"Kalhori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarti","family":"Kolluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omely","family":"Marte-Salcedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alemush","family":"Imeru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0110-881X","authenticated-orcid":false,"given":"Martha","family":"Nason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei K.","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope","family":"Decederfelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Raiten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen C. C.","family":"Hume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihyun E.","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ijeoma","family":"Ikpeama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"KC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumana","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tooba","family":"Murshedkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. W. Preston","family":"Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Manoj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Gunasekera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2048-0131","authenticated-orcid":false,"given":"Sean C.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"March","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1293-2097","authenticated-orcid":false,"given":"Sangeeta N.","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Billingsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Kim Lee","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2946-5456","authenticated-orcid":false,"given":"Thomas L.","family":"Richie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4483-5005","authenticated-orcid":false,"given":"Patrick E.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"3684_CR1","unstructured":"WHO. World Malaria Report 2019 (World Health Organization, 2019)."},{"key":"3684_CR2","doi-asserted-by":"publisher","first-page":"e1001685","DOI":"10.1371\/journal.pmed.1001685","volume":"11","author":"The RTS,S Clinical Trials Partnership","year":"2014","unstructured":"The RTS,S Clinical Trials Partnership. Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 11, e1001685 (2014).","journal-title":"PLoS Med."},{"key":"3684_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"RTS,S Clinical Trials Partnership","year":"2015","unstructured":"RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31\u201345 (2015).","journal-title":"Lancet"},{"key":"3684_CR4","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","volume":"367","author":"The RTS,S Clinical Trials Partnership","year":"2012","unstructured":"The RTS,S Clinical Trials Partnership. A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367, 2284\u20132295 (2012).","journal-title":"N. Engl. J. Med."},{"key":"3684_CR5","doi-asserted-by":"publisher","first-page":"e89154","DOI":"10.1172\/jci.insight.89154","volume":"2","author":"JE Epstein","year":"2017","unstructured":"Epstein, J. E. et al. Protection against Plasmodium falciparum malaria by PfSPZ vaccine. JCI Insight 2, e89154 (2017).","journal-title":"JCI Insight"},{"key":"3684_CR6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.4269\/ajtmh.17-1014","volume":"99","author":"SA Jongo","year":"2018","unstructured":"Jongo, S. A. et al. Safety, immunogenicity, and protective efficacy against controlled human malaria infection of Plasmodium falciparum sporozoite vaccine in Tanzanian adults. Am. J. Trop. Med. Hyg. 99, 338\u2013349 (2018).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"3684_CR7","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1073\/pnas.1615324114","volume":"114","author":"KE Lyke","year":"2017","unstructured":"Lyke, K. E. et al. Attenuated PfSPZ vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc. Natl Acad. Sci. USA 114, 2711\u20132716 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3684_CR8","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1126\/science.1241800","volume":"341","author":"RA Seder","year":"2013","unstructured":"Seder, R. A. et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341, 1359\u20131365 (2013).","journal-title":"Science"},{"key":"3684_CR9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(17)30104-4","volume":"17","author":"MS Sissoko","year":"2017","unstructured":"Sissoko, M. S. et al. Safety and efficacy of PfSPZ vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect. Dis. 17, 498\u2013509 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"3684_CR10","unstructured":"Sissoko, M. S. et al. Three dose regimen of PfSPZ vaccine protects adult Malians against Plasmodium falciparum through an intense transmission season: a randomised, controlled phase I trial. Lancet Infect. Dis. (in the press)."},{"key":"3684_CR11","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.chom.2011.05.008","volume":"9","author":"NS Butler","year":"2011","unstructured":"Butler, N. S. et al. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 9, 451\u2013462 (2011).","journal-title":"Cell Host Microbe"},{"key":"3684_CR12","doi-asserted-by":"crossref","unstructured":"Kublin, J. G. et al.\u00a0 Complete attenuation of genetically engineered sporozoites in human subjects. Sci. Transl. Med. 9, eaad9099\u00a0(2017).","DOI":"10.1126\/scitranslmed.aad9099"},{"key":"3684_CR13","doi-asserted-by":"publisher","first-page":"eaaz5629","DOI":"10.1126\/scitranslmed.aaz5629","volume":"12","author":"M Roestenberg","year":"2020","unstructured":"Roestenberg, M. et al. A double-blind, placebo-controlled phase 1\/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1. Sci. Transl. Med. 12, eaaz5629 (2020).","journal-title":"Sci. Transl. Med."},{"key":"3684_CR14","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1056\/NEJMoa0805832","volume":"361","author":"M Roestenberg","year":"2009","unstructured":"Roestenberg, M. et al. Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med. 361, 468\u2013477 (2009).","journal-title":"N. Engl. J. Med."},{"key":"3684_CR15","doi-asserted-by":"publisher","first-page":"e112910","DOI":"10.1371\/journal.pone.0112910","volume":"9","author":"EM Bijker","year":"2014","unstructured":"Bijker, E. M. et al. Sporozoite immunization of human volunteers under mefloquine prophylaxis is safe, immunogenic and protective: a double-blind randomized controlled clinical trial. PLoS ONE 9, e112910 (2014).","journal-title":"PLoS ONE"},{"key":"3684_CR16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3389\/fmicb.2015.00283","volume":"6","author":"T Sahu","year":"2015","unstructured":"Sahu, T. et al. Chloroquine neither eliminates liver stage parasites nor delays their development in a murine chemoprophylaxis vaccination model. Front. Microbiol. 6, 283 (2015).","journal-title":"Front. Microbiol."},{"key":"3684_CR17","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1086\/339409","volume":"185","author":"SL Hoffman","year":"2002","unstructured":"Hoffman, S. L. et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 185, 1155\u20131164 (2002).","journal-title":"J. Infect. Dis."},{"key":"3684_CR18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature21060","volume":"542","author":"B Mordm\u00fcller","year":"2017","unstructured":"Mordm\u00fcller, B. et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 542, 445\u2013449 (2017).","journal-title":"Nature"},{"key":"3684_CR19","doi-asserted-by":"publisher","first-page":"e0124243","DOI":"10.1371\/journal.pone.0124243","volume":"10","author":"R Schats","year":"2015","unstructured":"Schats, R. et al. Heterologous protection against malaria after immunization with Plasmodium falciparum sporozoites. PLoS ONE 10, e0124243 (2015).","journal-title":"PLoS ONE"},{"key":"3684_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0923-4","volume":"15","author":"J Walk","year":"2017","unstructured":"Walk, J. et al. Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial. BMC Med. 15, 168 (2017).","journal-title":"BMC Med."},{"key":"3684_CR21","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1128\/AAC.01717-10","volume":"55","author":"J Friesen","year":"2011","unstructured":"Friesen, J., Borrmann, S. & Matuschewski, K. Induction of antimalaria immunity by pyrimethamine prophylaxis during exposure to sporozoites is curtailed by parasite resistance. Antimicrob. Agents Chemother. 55, 2760\u20132767 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"3684_CR22","doi-asserted-by":"publisher","first-page":"7002","DOI":"10.1016\/j.vaccine.2011.07.034","volume":"29","author":"J Friesen","year":"2011","unstructured":"Friesen, J. & Matuschewski, K. Comparative efficacy of pre-erythrocytic whole organism vaccine strategies against the malaria parasite. Vaccine 29, 7002\u20137008 (2011).","journal-title":"Vaccine"},{"key":"3684_CR23","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/cid\/ciz1010","volume":"71","author":"SA Healy","year":"2020","unstructured":"Healy, S. A. et al. Chemoprophylaxis vaccination: phase I study to explore stage-specific immunity to Plasmodium falciparum in US adults. Clin. Infect. Dis. 71, 1481\u20131490 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"3684_CR24","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/QCO.0000000000000002","volume":"26","author":"JE Epstein","year":"2013","unstructured":"Epstein, J. E. & Richie, T. L. The whole parasite, pre-erythrocytic stage approach to malaria vaccine development: a review. Curr. Opin. Infect. Dis. 26, 420\u2013428 (2013).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"3684_CR25","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.chom.2013.06.005","volume":"14","author":"S March","year":"2013","unstructured":"March, S. et al. A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax. Cell Host Microbe 14, 104\u2013115 (2013).","journal-title":"Cell Host Microbe"},{"key":"3684_CR26","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1038\/nprot.2015.128","volume":"10","author":"S March","year":"2015","unstructured":"March, S. et al. Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens. Nat. Protocols 10, 2027\u20132053 (2015).","journal-title":"Nat. Protocols"},{"key":"3684_CR27","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.chom.2018.01.002","volume":"23","author":"N Gural","year":"2018","unstructured":"Gural, N. et al. In vitro culture, drug sensitivity, and transcriptome of Plasmodium vivax hypnozoites. Cell Host Microbe 23, 395\u2013406.e4 (2018).","journal-title":"Cell Host Microbe"},{"key":"3684_CR28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2165\/00003088-198510030-00001","volume":"10","author":"NJ White","year":"1985","unstructured":"White, N. J. Clinical pharmacokinetics of antimalarial drugs. Clin. Pharmacokinet. 10, 187\u2013215 (1985).","journal-title":"Clin. Pharmacokinet."},{"key":"3684_CR29","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nm.4110","volume":"22","author":"AS Ishizuka","year":"2016","unstructured":"Ishizuka, A. S. et al. Protection against malaria at 1\u00a0year and immune correlates following PfSPZ vaccination. Nat. Med. 22, 614\u2013623 (2016).","journal-title":"Nat. Med."},{"key":"3684_CR30","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.4049\/jimmunol.1700314","volume":"199","author":"I Zaidi","year":"2017","unstructured":"Zaidi, I. et al. \u03b3\u03b4 T cells are required for the induction of sterile immunity during irradiated sporozoite vaccinations. J. Immunol. 199, 3781\u20133788 (2017).","journal-title":"J. Immunol."},{"key":"3684_CR31","doi-asserted-by":"publisher","first-page":"7513","DOI":"10.1016\/j.vaccine.2015.09.098","volume":"33","author":"W Nahrendorf","year":"2015","unstructured":"Nahrendorf, W., Scholzen, A., Sauerwein, R. W. & Langhorne, J. Cross-stage immunity for malaria vaccine development. Vaccine 33, 7513\u20137517 (2015).","journal-title":"Vaccine"},{"key":"3684_CR32","doi-asserted-by":"publisher","first-page":"e05165","DOI":"10.7554\/eLife.05165","volume":"4","author":"W Nahrendorf","year":"2015","unstructured":"Nahrendorf, W. et al. Blood-stage immunity to Plasmodium chabaudi malaria following chemoprophylaxis and sporozoite immunization. eLife 4, e05165 (2015).","journal-title":"eLife"},{"key":"3684_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0708-9","volume":"12","author":"KA Moser","year":"2020","unstructured":"Moser, K. A. et al. Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential. Genome Med. 12, 6 (2020).","journal-title":"Genome Med."},{"key":"3684_CR34","doi-asserted-by":"publisher","first-page":"7862","DOI":"10.1073\/pnas.1220360110","volume":"110","author":"EM Bijker","year":"2013","unstructured":"Bijker, E. M. et al. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc. Natl Acad. Sci. USA 110, 7862\u20137867 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3684_CR35","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.4049\/jimmunol.172.4.2487","volume":"172","author":"E Belnoue","year":"2004","unstructured":"Belnoue, E. et al. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J. Immunol. 172, 2487\u20132495 (2004).","journal-title":"J. Immunol."},{"key":"3684_CR36","doi-asserted-by":"crossref","unstructured":"Lyke, K. E. et al. Multidose priming and delayed boosting improve Plasmodium falciparum sporozoite vaccine efficacy against heterologous P. falciparum controlled human malaria infection. Clin. Infect. Dis. ciaa1294 (2020).","DOI":"10.1093\/cid\/ciaa1294"},{"key":"3684_CR37","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/81315","volume":"6","author":"SL Hoffman","year":"2000","unstructured":"Hoffman, S. L. & Doolan, D. L. Malaria vaccines-targeting infected hepatocytes. Nat. Med. 6, 1218\u20131219 (2000).","journal-title":"Nat. Med."},{"key":"3684_CR38","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1126\/science.1211548","volume":"334","author":"JE Epstein","year":"2011","unstructured":"Epstein, J. E. et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 334, 475\u2013480 (2011).","journal-title":"Science"},{"key":"3684_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-020-03175-y","volume":"19","author":"D Issiaka","year":"2020","unstructured":"Issiaka, D. et al. Impact of seasonal malaria chemoprevention on hospital admissions and mortality in children under 5\u00a0years of age in Ouelessebougou, Mali. Malar. J. 19, 103 (2020).","journal-title":"Malar. J."},{"key":"3684_CR40","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.4269\/ajtmh.18-0835","volume":"100","author":"SA Jongo","year":"2019","unstructured":"Jongo, S. A. et al. Safety and differential antibody and T-cell responses to the Plasmodium falciparum sporozoite malaria vaccine, PfSPZ vaccine, by age in Tanzanian adults, adolescents, children, and infants. Am. J. Trop. Med. Hyg. 100, 1433\u20131444 (2019).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"3684_CR41","doi-asserted-by":"crossref","unstructured":"Sulyok, Z. et al. Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial. Nat. Commun. 12,\u00a02518\u00a0\u00a0(2021)","DOI":"10.1038\/s41467-021-22740-w"},{"key":"3684_CR42","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1016\/j.vaccine.2013.08.007","volume":"31","author":"M Spring","year":"2013","unstructured":"Spring, M. et al. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine 31, 4975\u20134983 (2013).","journal-title":"Vaccine"},{"key":"3684_CR43","doi-asserted-by":"publisher","first-page":"e135589","DOI":"10.1172\/jci.insight.135589","volume":"5","author":"D Goswami","year":"2020","unstructured":"Goswami, D. et al. A replication-competent late liver stage-attenuated human malaria parasite. JCI Insight 5, e135589 (2020).","journal-title":"JCI Insight"},{"key":"3684_CR44","doi-asserted-by":"crossref","unstructured":"Roestenberg, M. et al. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am. J. Trop. Med. Hyg. 88, 5\u201313\u00a0(2013).","DOI":"10.4269\/ajtmh.2012.12-0613"},{"key":"3684_CR45","doi-asserted-by":"crossref","unstructured":"Mordm\u00fcller, B. et al. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malaria J. 14, 117\u00a0(2015).","DOI":"10.1186\/s12936-015-0628-0"},{"key":"3684_CR46","doi-asserted-by":"crossref","unstructured":"Laurens, M. B. et al. Dose-dependent infectivity of aseptic, purified, cryopreserved Plasmodium falciparum 7G8 sporozoites in malaria-naive adults. J. Infect. Dis. 220, 1962\u20131966\u00a0(2019).\u00a0","DOI":"10.1093\/infdis\/jiz410"},{"key":"3684_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-9-344","volume":"9","author":"PC Divis","year":"2010","unstructured":"Divis, P. C., Shokoples, S. E., Singh, B. & Yanow, S. K. A TaqMan real-time PCR assay for the detection and quantitation of Plasmodium knowlesi. Malar. J. 9, 344 (2010).","journal-title":"Malar. J."},{"key":"3684_CR48","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.4269\/ajtmh.19-0094","volume":"100","author":"AM Seilie","year":"2019","unstructured":"Seilie, A. M. et al. Beyond blood smears: qualification of Plasmodium 18S rRNA as a biomarker for controlled human malaria infections. Am. J. Trop. Med. Hyg. 100, 1466\u20131476 (2019).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"3684_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-017-2152-x","volume":"17","author":"PM Luethy","year":"2018","unstructured":"Luethy, P. M. et al. Diagnostic challenges of prolonged post-treatment clearance of Plasmodium nucleic acids in a pre-transplant autosplenectomized patient with sickle cell disease. Malar. J. 17, 23 (2018).","journal-title":"Malar. J."},{"key":"3684_CR50","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1128\/JCM.42.12.5636-5643.2004","volume":"42","author":"M Rougemont","year":"2004","unstructured":"Rougemont, M. et al. Detection of four Plasmodium species in blood from humans by 18S rRNA gene subunit-based and species-specific real-time PCR assays. J. Clin. Microbiol. 42, 5636\u20135643 (2004).","journal-title":"J. Clin. Microbiol."},{"key":"3684_CR51","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/sim.7579","volume":"37","author":"EE Gabriel","year":"2018","unstructured":"Gabriel, E. E., Nason, M., Fay, M. P. & Follmann, D. A. A boundary-optimized rejection region test for the two-sample binomial problem. Stat. Med. 37, 1047\u20131058 (2018).","journal-title":"Stat. Med."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-021-03684-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-021-03684-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-021-03684-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T10:05:43Z","timestamp":1675505143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-021-03684-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":51,"journal-issue":{"issue":"7866","published-print":{"date-parts":[[2021,7,8]]}},"alternative-id":["3684"],"URL":"https:\/\/doi.org\/10.1038\/s41586-021-03684-z","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,30]]},"assertion":[{"value":"29 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.M., L.W.P.C., A.M., A.G., B.K.L.S., N.K.C., S.C., P.F.B., E.R.J., T.L.R. and S.L.H. are salaried, full-time employees of Sanaria, the developer and sponsor of Sanaria PfSPZ Vaccine. S.L.H. and B.K.L.S. also have financial interests in Sanaria. B.K.L.S. and S.L.H. are inventors on patents and patent applications that have been assigned to Sanaria. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}